Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
AudioCodes Q1 2026 Earnings Call - Voice AI and Recurring Revenue Momentum Accelerate
AudioCodes delivered a solid first quarter in 2026, with total revenues rising 2.9% year-over-year to $62.1 million. The company’s strategic pivot toward a voice AI-driven hybrid cloud model is gainin...
- Total Q1 2026 revenue reached $62.1 million, up 2.9% year-over-year, with services accounting for 54.7% of the mix.
- Live managed services and conversational AI combined to generate $80 million in annual recurring revenue, growing nearly 20% year-over-year.
- Conversational AI revenue grew over 50% year-over-year, representing roughly 8% of total revenue and signaling rapid enterprise adoption.
- +9 more takeaways
Neuronetics Q1 2026 Earnings Call - New CEO Pivots Strategy Amid Cash Constraints and Strategic Review Pressure
Neuronetics reported Q1 2026 revenue of $34.5 million, an 8% year-over-year increase, driven by a 15% rise in U.S. clinic revenue. The new CEO, Dan Reuvers, emphasized a shift toward flexible commerci...
- Total revenue increased 8% year-over-year to $34.5 million, primarily driven by a 15% surge in U.S. clinic revenue.
- U.S. NeuroStar system revenue grew 13% to $3.2 million, with 34 systems shipped, up 10% year-over-year.
- U.S. treatment session revenue declined 5% to $9.1 million, offsetting a 3.5% increase in treatment utilization due to lower customer inventory levels.
- +9 more takeaways
SelectQuote Q3 Fiscal 2026 Earnings Call - Surge in Cash Flow Visibility Amid Valuation Disconnect
SelectQuote delivered a robust third fiscal quarter, posting $431 million in revenue and $45 million in adjusted EBITDA, driven by resilient performance in its Medicare Advantage and healthcare servic...
- SelectQuote reported $431 million in revenue for Q3 fiscal 2026, a 6% year-over-year increase, demonstrating resilience across its core segments.
- Adjusted EBITDA reached $45 million, representing an 18% year-over-year growth, though this was partially boosted by a non-recurring favorable adjustment.
- The senior business generated $183 million in revenue, up 8% year-over-year, driven by a 4% increase in approved Medicare Advantage policies and strong agent productivity.
- +7 more takeaways
Fresenius Medical Care Q1 2026 Earnings Call - Accelerated Buyback and TDAPA Cliff Loom
Fresenius Medical Care delivered a solid Q1 2026 with 4% organic revenue growth and 10% operating income expansion, driven by the TDAPA tailwind and the FME25+ cost program. The company accelerated it...
- Organic revenue grew 4% in Q1 2026, with operating income up 10%, reflecting strong margin expansion to 10.1%.
- The company completed its EUR 1 billion share buyback in under a year, repurchasing 24.8 million shares (8.5% of capital) and maintaining a 2.6x net leverage ratio.
- TDAPA regulations provided an EUR 80 million tailwind in Q1, but a significant headwind is expected in H2 2026, creating a clear earnings cliff.
- +9 more takeaways
First Watch Restaurant Group Q1 2026 Earnings Call - Digital Marketing ROI and Menu Innovation Drive Profitable Growth
First Watch Restaurant Group delivered a strong first quarter for fiscal 2026, with same-store sales growth of 2.8% and a restaurant-level operating profit margin of 18.5%. The company successfully ro...
- First Watch reported Q1 2026 same-store sales growth of 2.8%, driven by a positive mix shift from its new core menu and seasonal offerings, despite a 2% decline in traffic that was partially weather-related.
- Restaurant-level operating profit margin expanded 200 basis points to 18.5%, supported by carried pricing, commodity deflation on eggs and avocados, and a 90 basis point improvement in labor costs.
- The company accelerated its digital marketing campaign to 75% of the restaurant base, up from one-third in 2025, and is already seeing positive ROI, prompting a pull-forward of several million in marketing spend into Q2.
- +7 more takeaways
Enpro Industries Q1 2026 Earnings Call - Accelerating Semiconductor Demand Drives Raised Guidance
Enpro Industries kicked off 2026 with force, posting 11% sales growth and 13% adjusted EBITDA growth, fueled by a steepening demand curve in its Advanced Surface Technologies (AST) segment and seamles...
- Total company sales rose nearly 11% year-over-year to $303 million, with AST sales up over 11% and Sealing Technologies up 10.8%.
- Adjusted EBITDA increased nearly 13% to $76.4 million, with the total company adjusted EBITDA margin expanding 40 basis points year-over-year to 25.2%.
- Management raised full-year 2026 guidance, now expecting total sales growth of 10%-14% and adjusted EBITDA of $315 million to $330 million.
- +7 more takeaways
FTC Solar Q1 2026 Earnings Call - New CEO Anthony Carroll Takes the Helm as Backlog Surges and Bookings Accelerate
FTC Solar reported a rougher first quarter on paper, with revenue of $17.3 million missing its target range due to a single delayed project. But the real story is the commercial momentum building behi...
- FTC Solar appointed Anthony Carroll as President and CEO, succeeding Yann Brandt. Carroll brings a track record of scaling operations at billion-dollar energy and construction firms, signaling a strategic shift toward aggressive growth and global expansion.
- Q1 revenue came in at $17.3 million, missing the company's guidance range due to a single delayed project expected to contribute $3 to $4 million. However, operating expenses came in better than expected, providing some offset.
- The company secured a major 1-gigawatt Safe Harbor project award for a private equity-backed portfolio company with high-profile off-takers. The first tranche is contracted, and the project is expected to add triple-digit millions to revenue in the back half of 2026 and into 2027.
- +7 more takeaways
Rhythm Pharmaceuticals Q1 2026 Earnings Call - Acquired HO Launch Accelerates with 150+ Start Forms in Six Weeks
Rhythm Pharmaceuticals delivered a strong Q1 2026, driven by steady growth in its ultra-rare Bardet-Biedl syndrome (BBS) base business and the rapid commercial launch of IMCIVREE for acquired hypothal...
- U.S. net revenues reached $60.1 million in Q1 2026, up 5% sequentially, with $36.9 million from the U.S. and $23.2 million internationally.
- IMCIVREE for acquired hypothalamic obesity (HO) launched in the U.S. on March 19, capturing 150+ start forms in six weeks, with ~40 from clinical trial conversions and 80% from new prescribers.
- HO launch pace outpaces Bardet-Biedl syndrome (BBS); early payer approval rates improved due to prior BBS-based education, though specific HO policies expected in 3–9 months.
- +12 more takeaways
Embecta Corp Q2 FY2026 Earnings Call - U.S. Pen Needle Share Loss Drives Guidance Cut and Owen Mumford Acquisition
Embecta delivered a disappointing second quarter of fiscal 2026, with consolidated revenues falling 14.4% year-over-year as U.S. pen needle sales collapsed under competitive share loss and broader mar...
- U.S. Revenue Collapse: U.S. revenue fell 29.4% year-over-year, driven primarily by competitive share loss at a single major customer and broader market softness in insulin pen prescriptions.
- Guidance Cut: Full-year FY2026 revenue guidance is lowered to $1.015 billion–$1.035 billion, reflecting a ~$75 million reduction in organic revenue expectations compared to prior low-end guidance.
- Pen Needle Headwinds: Pen needles, which make up ~70% of the guidance reduction, suffered from ~$25 million in share loss and ~$20 million in market volume softness, exacerbated by patients shifting to lower-cost channels.
- +7 more takeaways
DuPont Q1 2026 Earnings Call - Strong Q1 Results and Raised Full-Year Guidance Driven by Healthcare, Aerospace, and Productivity Gains
DuPont delivered a strong start to 2026, beating guidance with 2% organic sales growth, 130 basis points of pro forma margin expansion, and double-digit adjusted EPS growth. The company closed the $1....
- DuPont reported Q1 2026 net sales of $1.7 billion, up 4% year-over-year, driven by 2% organic growth and a 2% currency benefit. Results exceeded prior guidance.
- Operating EBITDA surged 15% to $414 million, with pro forma margins expanding 130 basis points to 24.6%, reflecting strong operational execution and favorable mix.
- Adjusted EPS reached $0.55 on a reported basis (up 53% YoY) and $0.55 on a pro forma basis (up 20% YoY), beating consensus expectations.
- +9 more takeaways